Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director | 737.69k | -- | 1975 |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board | -- | -- | 1972 |
| Mr. Robert Hendriks | Senior VP of Finance | -- | -- | -- |
| Mr. Alexander Zurcher | COO & Member of Management Board | -- | -- | 1975 |
| Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board | -- | -- | 1970 |
| Dr. Philippe Legenne M.B.A., M.D. | Chief Medical Officer & Member of the Management Board | -- | -- | 1966 |
| Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology | -- | -- | -- |
| Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | -- | -- | -- |
| Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior VP Legal & Business Development | -- | -- | -- |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant | -- | -- | 1956 |
Molecular Partners AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 158
Description
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Corporate Governance
Upcoming Events
March 6, 2025 at 9:00 PM UTC
Molecular Partners AG Earnings Date